Treatment with the vaccine did not improve progression-free survival in patients with HPV16-positive cervical and anogenital tumors.

Drugmakers and insurers are exploring different payment schemes for expensive, potentially curative treatments, particularly ones tied to patient response.

Certain members of MotivHealth's HSA-based insurance plans will have access to DecisionRx's medication therapy optimization program.

With A$45 million in funding, the group will focus on research developing safer therapies and clinical trial programs for pediatric cancer treatment.